Skip to main content
Premium Trial:

Request an Annual Quote

Cellix Raises $1.4M in Second-Round Funding to Develop Cell-Based Screening Platform

NEW YORK (GenomeWeb News) – Cellix, a Dublin, Ireland-based developer of cell-based screening tools, said today that it has raised €1.1 million ($1.4 million) in second-round investment.
 
The company previously raised €800,000 in December 2006.
 
Cellix said that the new financing, provided by NCB Ventures of Ireland and OTC Asset Management of France, will enable it to accelerate development and commercialization of its Venaflux screening platform to address a range of therapeutic areas, including atherosclerosis, diabetes, oncology, and autoimmune disorders. 
 
VenaFlux measures cell adhesion to antibody-coated or endothelial-cell cultured microchannels in order to mimic human blood flow. The company said that it is seeing “significant growth” for the platform, which is currently in use at AstraZeneca, Pfizer, Sanofi-Aventis, and Servier.
 
Cellix will use the financing to support continued R&D “as well as further expansion into international markets.”

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.